HD-OPM Archive
Topics › Statins

WOSCOPS 20-year follow-up: 5 years of pravastatin gave lasting mortality and event benefit

Gokhan Can · Apr 07, 2026 · ♥ 7 reactions · 1 comments · original Facebook post
StatinsLDL, ApoB & lipid panel
AI summary & key facts

Describes the 20-year follow-up of the West of Scotland Coronary Prevention Study: 5 years of pravastatin in middle-aged men with high cholesterol and no prior CHD produced a lasting legacy effect, with reduced all-cause, CV and coronary mortality and fewer heart failure and MI hospitalizations. No excess cancer or non-CV mortality was seen.

Statins' Lasting Impact on Cardiovascular Health

The 20-year follow-up of the West of Scotland Coronary Prevention Study (WOSCOPS) demonstrates a significant, long-lasting "legacy effect" of statin therapy for the primary prevention of cardiovascular disease. Originally a 5-year trial comparing pravastatin to a placebo in middle-aged men with hypercholesterolemia but no prior coronary heart disease, the extended 20-year observational follow-up revealed that the initial 5-year treatment period led to persistent health benefits. Specifically, the pravastatin group experienced significant reductions in all-cause mortality, cardiovascular and coronary heart disease mortality, and hospitalizations for heart failure and myocardial infarction. Furthermore, the long-term data confirmed the safety of pravastatin, showing no increased risk of cancer or non-cardiovascular mortality, ultimately supporting the early use of statins to positively alter the lifetime trajectory of atherosclerotic disease.

Paper · Glob Cardiol Sci Pract · 2016Legacy effect of statins: 20-year follow up of the West of Scotland Coronary Prevention Study (WOSCOPS).pmc.ncbi.nlm.nih.gov

Research cited

#mortality#cardiovascular#statins#heartdisease#prevention#cardiovascularhealth#cardiovasculardisease#heartfailure
← newer: Admin opinion: avoid pesticides because they may disrupt theolder: Statins cut deaths 31% in people 80+, showing absolute benef →